For Immediate Release
Chicago, IL – March 21, 2019 – Zacks Market Edge is a podcast hosted weekly by cks Stock Strategist Tracey Ryniec. Every week, Tracey will be joined by guests to discuss the hottest investing topics in stocks, bonds and ETFs and how it impacts your life. To listen to the podcast, click here:
Please use the Soundcloud link from this URL for the PR. Thanks: https://www.zacks.com/stock/news/362414/nash-allergies-and-beauty-stocks-invest-or-not
NASH, Allergies and Beauty Stocks: Invest or Not?
Welcome to Episode #170 of the Zacks Market Edge Podcast.
Every week, host and Zacks stock strategist, Tracey Ryniec, will be joined by guests to discuss the hottest investing topics in stocks, bonds and ETFs and how it impacts your life.
In this episode, Tracey is going solo to discuss the latest biopharmaceutical updates.
Some of them have trendy names like NASH, but others are often not discussed like treatments for peanut allergies and beauty products like breast implants and Botox.
Who is close to getting a new product approved?
And what about investing in those in the largest categories, like heart disease?
These are exciting areas for investors, but there’s still risk.
Should You Invest in the Hot Biopharmaceutical Stocks?
1. Edwards Lifesciences (EW - Free Report) just broke out to another new high. This giant in the heart disease category isn’t cheap, with a forward P/E of 36, but it’s expected to see double digit earnings growth in both 2019 and 2020.
2. Exact Sciences (EXAS - Free Report) isn’t expected to see positive earnings in 2019 or 2020 even though sales are soaring for this colon cancer testing company. Sales are expected to be up another 60.2% in 2019 and 47.5% in 2020 though.
3. Aimmune Therapeutics (AIMT - Free Report) develops treatments for life threatening food allergies, including peanut and egg allergies. The BLA for AR101 has been submitted to the FDA for treatment of the peanut allergy in children and adolescents ages 4-17. It was the first company to pass a Phase 3 study for peanuts. It also has a Phase 2 for egg allergies that is ongoing.
4. Allergan is the king of Botox. Last year, that product generated over $3.5 billion in revenue. And customers are getting younger and younger thanks to the pressure to appear a certain way in selfies on Instagram and Snap. But Botox, and Allergan’s filler product, Juvederm, face competition. Shares are trading at just 9.2x as analysts are wondering where future growth is going to come from.
5. Evolus (EOLS - Free Report) is the Allergan threat. On Feb 1, it got FDA approval for Jeuveau for frown lines. While earnings are expected to be a loss of $3.25 in 2019, they improve to a loss of just $1.38 by 2020. Watch for the possibility of European approval, which would greatly increase its market possibilities.
Questions investors should ask is, how much cash does the company have to ride out the approval process on a new drug or treatment?
And how expensive is the sales and marketing going to be if they do get a product to market?
What else should investors know about investing in the latest medical breakthroughs?
Tune into this week’s podcast to find out.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +98%, +119% and +164% in as little as 1 month. The stocks in this report could perform even better.
See these 7 breakthrough stocks now>>
Follow us on Twitter: https://twitter.com/zacksresearch
Join us on Facebook: https://www.facebook.com/home.php#/pages/Zacks-Investment-Research/57553657748?ref=ts
Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates.
Zacks Investment Research
800-767-3771 ext. 9339
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.